Abstracts OBJECTIVE: The cost-effectiveness of bone mineral density (BMD) screening and hormone replacement therapy for individuals with osteoporosis and osteopenia are well documented. The objective of this study was to estimate the economic impact of administering supplemental calcium and vitamin D3 to post-menopausal women with unknown BMD but such easily identifiable risk factors as advancing age, maternal family history of hip fractures, smoking, and prior fragility fractures after the age of 50 in Sweden.
OBJECTIVES: Many drugs show long-term rather than short-term benefits. Moreover, most clinical studies were too short to give evidence of cost savings. Therefore, we developed a simulation model to estimate the costs and benefits of BMI lowering drugs within a time frame of 10 years. We applied this simulation, a Markov model, to data from 4429 patients (20 studies) treated with the weight-management agent sibutramine or placebo. Both groups also received diet and exercise advice. METHODS: As major savings of lipid and BMI lowering drugs will be induced by reductions incidence rates for hypertension, CHD and diabetes (H-CHD-D), we restricted our model to these diseases. We chose a time frame of 10 years. In order to estimate changes in the incidence rates of H-CHD-D we used risk-equations data derived from large epidemiological studies. Our Markov model contains the following disease states: no disease; only hypertension; diabetes without CHD; CHD, and death. We estimated the transition probabilities by using the respective risk equation. Finally, each state was linked to annual costs. Using this simulation, we could estimate the individual costs for hypertension, CHD, and diabetes for each of the patients within the time frame of 10 years. The mean difference in costs between the sibutramine and placebo groups were considered to be savings induced by the sibutramine therapy. RESULTS: The 10-year incidence rates (sibutramine vs. placebo) were 22.3% vs. 33.8% (hypertension), 4.5% vs. 6.1% (CHD), and 19.4% vs. 21.3% (diabetes). The mean costs induced by H-CHD-D were 8042 DM for sibutramine and 9671 DM for placebo, a reduction of 1629 DM. CONCLUSION: Considering annual sibutramine costs of 912 DM, a net benefit of 717 DM over 10 years per patient results. This is a conservative estimate as only three diseases related to obesity were included.
